Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 2Phase 1/2 2

Status

Completed 5Active not recruiting 3Withdrawn 2Recruiting 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Leukemia 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 28pembrolizumab 22Bevacizumab 18Fluorouracil 17Cisplatin 17Nivolumab 16Capecitabine 16Leucovorin 15Dexamethasone 14Carboplatin 13avelumab 12Oxaliplatin 12Radiosurgery 11Gemcitabine 11Rituximab 10Radiotherapy 10Lenalidomide 10ALT-803 10venetoclax 9fludarabine 9Taxes 9Omacor 9Azacitidine 9130-nm albumin-bound paclitaxel 9Paclitaxel 8Docetaxel 8Bortezomib 8fludarabine phosphate 7Melphalan 7Irinotecan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × Leukapheresis × Clear all
NCT03100877 2017-12-13

Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma

City of Hope Medical Center

Phase 1/2 Withdrawn
Plasma cell

Multiple Myeloma

NCT01326273 2015-06-08

Autologous Cytomegalovirus (CMV) Specific CD8+ T Cells as Treatment for CMV Reactivation

Imperial College London

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡